Rituximab therapy for primary glomerulonephritis: Report on two cases

Table 2 Literature review: Adverse events during rituximab therapy for primary membranous and membranoproliferative glomerulonephritis

Ref.	n	Rituximab treatment dose	Follow-up period	Concomitant therapy	Response to RTX	Side-effects after RTX
Fervenza et al[2]	15	1 g × 2, on days 1 and 15	12 mo	ACE-I + ARB	Complete (n = 2) or partial remission (n = 6)	Nonserious transient AE (n = 10) pneumonia (n = 1)
Segarra [3]	13	375 mg/m2 once weekly × 4	30 mo	Tac (n = 10), CyA (n = 3), CCS (n = 3)	Partial remission (n = 13)	None
Fervenza et al[4]	20	375 mg/m2 once weekly × 4	24 mo	ACE-I + ARB	Complete (n = 4) or partial remission (n = 12)	Nonserious transient AE (n = 11) pneumonia (n = 1)
Michel et al[5]	28	375 mg/m2 once weekly × 2 or 3 or 4 (n = 27) 1 g × 2, on days 1 and 15 (n = 1)	12 mo	ACE-I + ARB, CCS (n = 1), Tac (n = 1)	Complete (n = 6) or partial remission (n = 13)	Nonserious transient AE (few)
Ruggenenti et al[6]	100	375 mg/m2 once weekly × 4	29 mo	CCS	Complete (n = 27) or partial remission (n = 38)	Nonserious transient AE (n = 28)
Dillon et al[7]	6	1 g × 2, on days 1 and 15	12 mo	ACE-I + ARB	Complete (n = 2) or partial remission (n = 3)	None
Kong et al[8]	13	500 mg × 1 (n = 6)	31.5 mo	CCS (os) (n = 9)	Remission (n = 19)	Nonserious transient AE (n = 8)
		500 mg × 2 (n = 3)		CyA (n = 2)		Pneumonia (n = 1)
		500 mg × 4 (n = 4)		CCS (iv) (n = 2)

ACE-I: Angiotensin converting enzyme inhibitors; AE: Adverse events; ARB: Angiotensin receptor blockers; CCS: Corticosteroids [by intravenous (iv) or oral (os) route]; CyA: Cyclosporine; MN: Membranous nephropathy; MPGN: Membranoproliferative glomerulonephritis; Tac: Tacrolimus; RTX: Rituximab.